Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan

Next Previous
X
Search
Trial Profile

Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Back pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 30 Sep 2016 Results of subgroup analysis based on the number of painful body sites (n=456) presented at the 16th World Congress on Pain.
    • 31 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information JapicCTI132129).
    • 21 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top